PRAGUE--(BUSINESS WIRE)--SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, today announced a license and option agreement with Synaffix B.V., a Lonza company, to develop ...
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback